Puma Biotechnology, Inc. (PBYI)

USD 2.77

(-5.14%)

Market Cap (In USD)

135.97 Million

Revenue (In USD)

235.63 Million

Net Income (In USD)

21.59 Million

Avg. Volume

468.1 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.23-7.73
PE
-
EPS
-
Beta Value
1.08
ISIN
US74587V1070
CUSIP
74587V107
CIK
1401667
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Alan H. Auerbach
Employee Count
-
Website
https://www.pumabiotechnology.com
Ipo Date
2012-04-24
Details
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.